论文部分内容阅读
目的观察同步放化疗加热疗治疗局部晚期非小细胞肺癌(NSCLC)的临床近期疗效和不良反应。方法将64例Ⅲ期非小细胞肺癌患者随机分成观察组和对照组,每组32例。观察组患者给予同步放化疗联合热疗,对照组患者给予同步放化疗。治疗结束后2~3个月复查胸部CT评价临床近期疗效和不良反应。结果观察组患者总有效率(90.6%)高于对照组(81.3%),但差异无统计学意义(2=0.474,P=0.237)。治疗过程中主要不良反应为放射性食管炎、放射性肺炎、白细胞减少、血红蛋白减少等,且多为Ⅰ~Ⅱ度,观察组患者的不良反应显著低于对照组,差异有统计学意义(P<0.05)。结论热疗联合同步放化疗治疗局部晚期非小细胞肺癌近期疗效肯定,不良反应小,患者耐受性好。
Objective To observe the clinical efficacy and side effects of concurrent chemoradiotherapy and thermotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods 64 patients with stage Ⅲ non-small cell lung cancer were randomly divided into observation group and control group, 32 cases in each group. Patients in the observation group were treated with concurrent chemoradiotherapy combined with hyperthermia, and patients in the control group were treated with concurrent chemoradiation. Chest CT was reviewed 2 to 3 months after the end of treatment to evaluate the clinical efficacy and adverse reactions. Results The total effective rate (90.6%) in observation group was higher than that in control group (81.3%), but the difference was not statistically significant (2 = 0.474, P = 0.237). The main adverse reactions in the course of treatment were radiation esophagitis, radiation pneumonitis, leucopenia and hemoglobin decrease, mostly in grade Ⅰ ~ Ⅱ. The adverse reactions in the observation group were significantly lower than those in the control group (P <0.05 ). Conclusions Hyperthermia combined with concurrent chemoradiotherapy for the treatment of locally advanced non-small cell lung cancer has a positive curative effect in the near future, with small adverse reactions and good patient tolerance.